MedTrace Logo

A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects

NCT04587011 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-12-28

No results posted yet for this study

Summary

The main purpose of this study is to explore the pharmacokinetics, pharmacodynamics and safety after twice-daily dosing of tegoprazan tablets in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Tegoprazan dose A or placebo

Tegoprazan A mg or placebo taken orally twice daily for 3 days.

DRUG

Tegoprazan dose B or placebo

Tegoprazan B mg or placebo taken orally twice daily for 3 days.

DRUG

Tegoprazan dose C or placebo

Tegoprazan C mg or placebo taken orally twice daily for 3 days.

DRUG

Tegoprazan dose D or placebo

Tegoprazan D mg or placebo taken orally twice daily for 3 days.

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Jong Lyul Kim, MD, PhD · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2021-03-31
Completion
2021-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04587011 on ClinicalTrials.gov